Sunday 18 October 2026
Export NERV’s income statement to Excel — free account
Minerva Neurosciences, Inc
NERV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 183.7% and free cash flow fell 553.5%, each against the same quarter a year earlier.
2.35
0.07
−2.89%
Follow NERV
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 27.60 | 38.41 | 40.00 | 32.08 | 14.48 | 6.30 | 1.26 | 1.43 | 2.06 | 1.15 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 126.72 | 100.80 | 103.60 | 70.64 | 121.72 | 30.00 | 15.27 | 13.22 | 13.49 | 12.46 | |||||
| People | |||||||||||||||
| People | Employees | 11 | 12 | 13 | 13 | 11 | 9 | 9 | 9 | 8 | 7 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 3.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 41 | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (31) | (41) | (50) | (74) | 2 | (52) | (32) | (30) | 1 | (293) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 4.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (31) | (32) | (50) | (72) | 2 | (50) | (32) | (30) | 1 | (293) | |||||
| Depreciation | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (7.92) | (6.64) | (10.32) | (14.80) | 0.40 | (9.36) | (6.01) | (4.61) | 0.19 | (34.67) | |||||
| Cash flow | (6.52) | 0.65 | (8.65) | (8.91) | (6.63) | (4.61) | (4.61) | (2.27) | (2.58) | (1.60) | |||||
| Capex | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (6.52) | 0.64 | (8.65) | (8.91) | (6.63) | (4.61) | (4.62) | (2.27) | (2.58) | (1.60) | |||||
| Book value | 26.90 | 27.75 | 18.61 | 5.70 | 10.32 | 1.49 | (3.75) | (4.37) | (3.39) | (16.63) | |||||
| Shares, m | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 7 | 8 | 8 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 29.25 | — | — | — | — | — | ||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| P/B | — | — | — | — | 1.81 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (2.16) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (26) | 3 | (42) | (43) | (34) | (25) | (25) | (15) | (20) | (14) | ||||
| Capex | — | 0 | — | — | — | — | 0 | — | — | — | |||||
| Free cash flow | (26) | 3 | (42) | (43) | (34) | (25) | (25) | (15) | (20) | (14) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 74 | 123 | 86 | 41 | 24 | 59 | 39 | 39 | 19 | 81 | ||||
| Total debt | 4 | 4 | — | 0 | 0 | — | 74 | — | — | — | |||||
| Net debt | (79) | (128) | (88) | (46) | (25) | (61) | (36) | (41) | (21) | (82) | |||||
| Shareholders’ equity | 106 | 132 | 90 | 28 | 53 | 8 | (20) | (28) | (26) | (141) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (28.81) | (19.91) | (31.08) | (66.64) | 2.87 | (74.07) | (48.57) | (53.59) | 3.06 | (434.34) | ||||
| ROIC | (70.51) | (766.68) | (1,491.63) | 0.00 | 4.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (38.49) | (26.54) | (45.23) | (122.30) | 4.83 | (164.60) | 532.98 | 123.78 | (5.31) | 352.58 | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Jun 2020
Charts ten years each
Minerva Neurosciences, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| ENGN enGene Therapeutics Inc | $114.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| SEER Seer, Inc. | $113.0M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| FHTX Foghorn Therapeutics Inc. | $112.2M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| GNLX Genelux Corporation | $112.2M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $112.2M | — (loss-making) | — (loss-making) | +9.72% (above 0%: growing) | n/m | −229.66% (below 0%: shrinking) | 94.90% | (622.89%) | Compare |
| Median of peers | $113.8M | — | — | +12.72% | — | −14.58% | 94.90% | (232.81%) |
Minerva Neurosciences, Inc (NERV) key facts
- Minerva Neurosciences, Inc (NERV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NERV traded at $2.35, a market capitalization of $115.6 million.
- Return on equity was 352.6% and debt-to-equity 0.00.